More information at http://www.biomarketgroup.com/market-research-report/t-cell-immunotherapy-market-2015
-2030.html
Published: 2015-OCT-13 Pages: 419
Format: PDF
Price: 2199 USD (Single User License)
Description
WHO has stated that the number of new cancer cases is expected to rise by 70% in the coming two decades. In the US alone, over one million people are diagnosed with cancer each year. Although cancer therapeutics continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. Specifically, immuno-oncology has been gradually nurtured by researchers over the last several years. Post an evident shift towards the development of therapeutics targeting cancer cells by harnessing immune system components, immunotherapeutics have gained a strong foothold in the pharmaceutical industry. After the early success of Immune Checkpoint Inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of this market.
Characterised by key features such as target specificity, adaptability and memory, T-cells have been effectively used as tools to mediate an immune response. T-cell immunotherapy is structured into segments comprising of CAR-T, TCR and TIL therapies. Academicians across the globe have significantly contributed by convening the initial research of the candidates; this has served as the framework for several start-ups / established industry players to drive the research forward.
The overall market is expected to make a huge leap over the coming decade. It is also important to highlight that various technology providers, aiming to develop T-cell immunotherapy products with improved efficacy and safety, have developed innovative platforms for engineering of the T-cells. Innovative research, lucrative rounds of VC funding, discovery of several novel targets, growing pipelines directed towards different therapeutic areas and encouraging clinical trial results have emerged as some of the other drivers of this market.
<strong>Synopsis</strong>
The “T-Cell Immunotherapy Market, 2015-2030” report provides an extensive study of the field of T-cell immunotherapy. With no marketed products, this emerging field is still in its infancy; the report provides a comprehensive view of the market segmented into the following three sub-groups: CAR-T therapies, TCR therapies and TIL therapies.
The market is characterised by a robust and opportunistic pipeline of products targeting both haematological cancers and solid tumours. As mentioned earlier, several research institutes have played a critical role in progression of the technology to its current stage. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania / The Children’s Hospital of Philadelphia), JCAR017 (Juno Therapeutics / Seattle Children’s Hospital), KTE-C19 and NY-ESO-1 TCR (Kite Pharma / National Cancer Institute), CD19-CAR (Takara Bio / Jichi Medical University) and LN-144 (Lion Biotechnologies / National Cancer Institute).
Encouraging clinical results have accelerated the progress of these therapies as they have emerged as one of the most effective ways of leveraging the potential of immune system.
The market is also seeing a growing interest from several technology providers, especially those with capabilities in genome editing and viral and non-viral gene transfer. In addition, several T-cell immunotherapy companies and technology providers are also developing innovative safety switches to manage known side effects such as cytokine release syndrome and B-cell aplasia.
One of the key objectives of the study is to review and quantify the opportunities laid by the innovative programs of both small and big pharma firms. The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms. Amongst other elements, the report elaborates on the
T-Cell Immunotherapy Market, 2015-2030
following key areas:
• The current state of the market with respect to key players, development stage of pipeline products (both clinical / preclinical) and targeted indications
• Partnerships which have taken place in the recent past covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, product development and co-commercialisation
• Innovative technological platforms, such as safety switches, which have contributed significantly in overcoming the existing gaps in therapy regimen
• Various investments and grants received by the companies focused in this area
• Therapeutic areas forming the current focus of developers, the gradual drift and opportunity offered by non-oncological therapeutic areas
• Competitive landscape, challenges and expected trend of market evolution within the three sub-segments • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing
The research, analysis and insights presented in this report include potential sales of several CAR-T therapies, TCR therapies and TIL therapies; this analysis is backed by a deep understanding of key drivers behind the growth. With most products still in the early stage of development, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.
<strong>Example Highlights</strong>
• During the course of our research, we identified over 180 T-cell therapies across various phases of development; CAR-T therapies (56%) are the most common, followed by TCR (25%) and TIL (19%) therapies.
• Research institutions, through investment of time, expertise and effort, have played a critical role in the design and development of novel CAR-Ts, TCRs and TILs. In fact, non-industrial players are involved in the development of around 65% of all the molecules in the pipeline; of these, 23% molecules are being developed jointly with industry participants. • Kite Pharma is the current flag-bearer; Novartis, Juno Therapeutics, CBMG, Celyad, Lion Biotechnologies,
Immunocore and Adaptimmune are some other well-known players. In addition, several start-ups have also emerged; these include (in alphabetical order) Altor BioScience, Applied Immune Technologies, Autolus, Carsgen, Celdara Medical, Eureka Therapeutics, Formula Pharmaceuticals, Mustang Therapeutics, Theravectys, TILT Biotherapeutics and TNK Therapeutics. • Engineered CAR-Ts with switch technologies are amongst the latest addition to the next-generation of T-cell immunotherapy pipeline. Players are developing CAR-Ts, TCRs and TILs which are more advanced and shall cater to a diverse array of patient needs. The coming few years are likely to witness a wave of innovative and successful T-cell therapies.
• Funding from VC firms and strategic investors has been a key enabler to the market’s growth. Over the last six years, we identified investments close to USD 3 billion across several start-ups and small firms; this trend is unlikely to subside in the near future.
• Overall, we believe the T-cell therapy market will be worth USD 30 billion by 2030, expanding at an annualised growth rate of over 100%; as TCR and TIL therapies gain ground, CAR-T therapies are likely to garner the most attention in near future.
<strong>Research Methodology</strong>
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for
The secondary sources of information include • Annual reports
• Investor presentations • SEC filings
• Industry databases
• News releases from company websites • Government policy documents
• Industry analysts’ views
While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
<strong>Chapter Outlines</strong>
Chapter 2 presents an executive summary of the report. It offers a high level view on where the T-cell immunotherapy market is headed in the mid-long term.
Chapter 3 provides a general introduction to T-cell immunotherapy. In this section, we have briefly discussed the
conventional therapies being used for oncology treatment, the advent of cancer immunotherapy and the reasons supporting the gradual emergence of T-cell therapies.
Chapter 4 provides a comprehensive landscape of the T-cell immunotherapy market. It includes information on therapies which are currently in different stages of development (both clinical and preclinical/discovery). The detailed analysis of this pipeline includes information on most commonly targeted indications, current phases of development, the targets and the type of developers for each of the therapies.
Chapter 5 focuses on CAR-T based therapies and highlights the prevailing trends pertaining to the on-going research in this field. It discusses the targets under investigation, current challenges, toxicity issues and several other relevant parameters. To credit the work of the eminent researchers across the globe, we have provided a mapping of prominent key opinion leaders in the CAR-T space. The chapter includes detailed profiles of the drugs under development. These profiles cover information such as history of development, clinical trial timeline, clinical trial results, manufacturing, estimated cost of treatment and treatment regimen.
Chapter 6 elaborates on TCR based therapies and highlights the current scenario pertaining to the on-going research in this field. As with the CAR-T therapies, to credit the work of eminent researchers across the globe, we have provided a mapping of prominent key opinion leaders in the TCR space. The chapter also includes detailed drug profiles of several drugs under development.
Chapter 7 elaborates on the TIL based therapies. As in the earlier two chapters, we have mapped the prominent key opinion leaders in the TIL space. The chapter also includes detailed profiles of the drugs under development.
Chapter 8 elaborates on the monetary opportunity presented by these therapies. It provides a comprehensive market forecast analysis for molecules in advanced stages of development (phase I/II, phase II and phase II/III) taking into consideration the target patient population, competition, likely adoption rate and price points.
Chapter 9 provides a competitive landscape of various T-cell therapies being developed for the treatment of commonly targeted indications such as haematological cancers and solid tumours. These indications have been the prime focus of companies developing T-cell immunotherapies. The chapter also highlights the epidemiological facts and currently available treatments for each indication.
Chapter 10 talks about emerging technological platforms which mediate/assist the growth of the T-cell market. It includes a detailed discussion on such novel and innovative technologies, along with brief information about the technology providers. Chapter 11 presents details on various investments and grants received by companies focused in the area of T-cell
immunotherapy. The analysis highlights the growing interest from the VC community and other strategic investors. Chapter 12 provides detailed company profiles of the leading players in the market. Each company profile includes
information such as financial performance, geographical presence, T-cell immunotherapy pipeline, recent collaborations and developments. Additionally, we have also provided details about funding instances relevant to each player.
Chapter 13 is a collection of transcripts of interviews conducted during the course of this study.
Chapter 14 summarises the overall report. In this chapter, we have provided a list of key takeaways and have expressed our independent opinion based on the research and analysis described in previous chapters.
Chapters 15 is an appendix, which provides tabulated data and the list of companies covered in the report.
Table of Contents
1 PREFACE
1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines
2 EXECUTIVE SUMMARY
3 INTRODUCTION 3.1. Chapter Overview
3.2. The Four Pillars of Cancer Therapy 3.3. Immunotherapy: Gaining a Strong Foothold 3.4. Immuno-Oncology (Cancer Immunotherapy) 3.5. Classification of Cancer Immunotherapies 3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy 3.5.1.2. Passive Immunotherapy 3.5.2. By Type of Target 3.5.3. By Approach
3.5.3.1 Activation and Suppression Immunotherapy 3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies 3.5.4.2. Bispecific Antibodies 3.5.4.3. Cytokines
3.5.4.4. Cell Based Therapies
3.6. T-Cell Therapies: Historical Evolution 3.7. T-Cell Therapies: Key Considerations 3.8. Strategies for Redirection of T-Cells
3.9. Methodologies for Transduction / Transfection of T-Cells 3.9.1. Retroviral Vectors
3.9.2. Lentiviral Vectors
3.9.3. Sleeping Beauty Transposon 3.10. Curative Potential of T-Cell Therapies 3.11. Roadblocks for T-Cell Therapies
4 MARKET LANDSCAPE 4.1. Introduction
4.2. Evolving T-Cell Therapy Space
4.3. T-Cell Therapy: A Promising and Robust Pipeline 4.4. CAR-T Cells Spearhead the T-Cell Market
4.5. Academia Research Leads On-going Activity in the T-Cell Space
4.6. T-Cell Market Poised to Expand Further: Several Molecules in Early Phases of Development 4.7. LimitedSuccess So Far: Restricted to Haematological Cancers/ Solid Tumours
4.8. Active Industry Players in the T-Cell Therapy Market
4.9. CD19 Continues to be the Most Popular Target for CAR-T Therapies 4.10. Targets Well Distributed for TCR Therapies
5 CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY 5.1. Introduction
5.2. History of Development 5.3. Current Research Landscape
5.4. Anatomical Layout of Chimeric Antigen Receptor 5.5. Generations of Chimeric Antigen Receptors 5.6. Development of CAR-T Cells
5.7. Lymphodepleting Therapy 5.8. Universal CAR-Ts 5.9. Route of Administration 5.10. Toxicity Issues
5.10.1. Cytokine Release Syndrome (CRS) 5.10.2. On-Target Off-Tumour Toxicity 5.10.3. Encephalopathy and B-Cell Aplasia 5.11. Management of Toxicity Issues 5.11.1. Target Selection
5.11.2. Cell Persistence 5.11.3. Receptor Expression 5.12. CD19: An Attractive Target 5.13. Other Targets
5.14. Challenges Associated with CAR-T Therapy 5.14.1. Competitive Risks 5.14.2. Clinical Risks 5.14.3. Regulatory Challenges 5.14.4. Commercial Risks 5.15. CTL019 (Novartis) 5.15.1. Introduction 5.15.2. History of Development 5.15.3. Development Status 5.15.4. Key Clinical Trial Results
5.15.5. Dosage Regimen, Treatment Cost and Manufacturing
5.16. JCAR (Juno Therapeutics) 5.16.1. Introduction
5.16.2. CAR-T Design 5.16.3. Development Status 5.16.4. Key Clinical Trial Results 5.16.4.1. JCAR014
5.16.4.2. JCAR015 5.16.4.3. JCAR017
5.16.5. Dosage Regimen and Manufacturing
5.17. KTE-C19 (Kite Pharma) 5.17.1. Introduction
5.17.2. Development Status 5.17.3. Key Clinical Trial Results
5.17.4. Dosage Regimen and Manufacturing 5.17.5. Next Generation eACT CAR Candidates
5.18. CD19 CAR (Takara Bio) 5.18.1. Introduction
5.18.2. Development Status 5.18.3. Key Clinical Trial Results
5.18.4. Dosage Regimen and Manufacturing
5.19. EFGRvIII CAR (Kite Pharma) 5.19.1. Introduction
5.19.2. Development Status
5.19.3. Dosage Regimen and Manufacturing
6 T-CELL RECEPTOR (TCR) THERAPIES 6.1. Introduction
6.2. Structure of T-Cell Receptor 6.3. Difference between CAR and TCR 6.4. History of Development
6.5. Current Research Landscape 6.6. Mechanism of Action 6.7. Safety Issues
6.7.1. Insertional Mutagenesis 6.7.2. On-Target Off-Tumour Toxicity
6.7.3. Cross Reactivity Issues 6.7.4. TCR Mismatch Pairing
6.8. Prerequisites of Antigen-Specific T-Cell Receptors
6.9. Identifying Strategies that Enhance the Anti-Tumour Efficacy 6.9.1. Affinity Enhanced TCRs
6.9.2. Soluble TCR Based Biologics
6.10. NY-ESO-1 TCR (Kite Pharma) 6.10.1. Introduction
6.10.2. Development Status 6.10.3. Dosage Regimen
6.11. MAGE A3/A6 TCR (Kite Pharma) 6.11.1. Introduction 6.11.2. Development Status 6.11.3. Dosage Regimen 6.12. JTCR016 (Juno Therapeutics) 6.12.1. Introduction 6.12.2. Development Status 6.12.3. Key Clinical Trial Results 6.12.4. Dosage Regimen
6.13. IMCgp100 (Immunocore) 6.13.1. Introduction
6.13.2. Development Status 6.13.3. Key Clinical Trial Results 6.13.4. Dosage Regimen
7. TUMOUR INFILTRATING LYMPHOCYTES (TIL) BASED THERAPIES 7.1. Introduction
7.2. Historical Background 7.3. Current Research Landscape
7.4. Strategies under Research to Enhance Efficacy 7.5. TIL: A Prognostic Tool for Various Indications
7.6. LN-144 (Formerly Contego) (Lion Biotechnologies) 7.6.1. Introduction
7.6.2. Development Status 7.6.3. Key Clinical Trial Results
7.6.4. Dosage Regimen and Manufacturing 7.6.5. Patent Portfolio
8. MARKET OPPORTUNITY 8.1. Chapter Overview 8.2. Scope and Limitations 8.3. Forecast Methodology
8.4. Overall T-Cell Therapy Market, 2015-2030
8.5. Overall Chimeric Antigen Receptor T-Cell (CAR-T) Market 8.5.1. CTL019 (Novartis)
8.5.1.1. Target Population 8.5.1.2. Sales Forecast
8.5.2. KTE-C19 (Kite Pharma) 8.5.2.1. Target Population 8.5.2.2. Sales Forecast
8.5.3. CD19 CAR-T (Takara Bio) 8.5.3.1. Target Population 8.5.3.2. Sales Forecast
8.5.4. EGFR CAR-T (Cellular Biomedicine Group) 8.5.4.1. Target Population
8.5.4.2. Sales Forecast
8.5.5. CD30 CAR-T (Cellular Biomedicine Group) 8.5.5.1. Target Population
8.5.5.2. Sales Forecast
8.5.6.1. Target Population 8.5.6.2. Sales Forecast
8.5.7. Anti-CD20 CAR T VectorTransduced T-Cells (Cellular Biomedicine Group) 8.5.7.1. Target Population
8.5.7.2. Sales Forecast
8.5.8. CD19 EBV CAR-T (Autolus) 8.5.8.1. Target Population 8.5.8.2. Sales Forecast
8.5.9. EGFRvIII (Kite Pharma) 8.5.9.1. Target Population 8.5.9.2. Sales Forecast
8.5.10. JCAR017 (Juno Therapeutics) 8.5.10.1. Target Population
8.5.10.2. Sales Forecast
8.5.11. JCAR0XX (Juno Therapeutics) 8.5.11.1. Target Population 8.5.11.2. Sales Forecast 8.6. Overall TCR Market 8.6.1. IMCgp100 (Immunocore) 8.6.1.1. Target Population 8.6.1.2. Sales Forecast
8.6.2. NY-ESO-1 TCR (Kite Pharma) 8.6.2.1. Target Population
8.6.2.2. Sales Forecast
8.6.3. HPV-16 E6-TCR (Kite Pharma) 8.6.3.1. Target Population
8.6.3.2. Sales Forecast
8.6.4. NY-ESO-1 TCR (Adaptimmune) 8.6.4.1. Target Population
8.6.4.2. Sales Forecast
8.6.5. ALT-801 (Altor BioScience) 8.6.5.1. Target Population 8.6.5.2. Sales Forecast
8.6.6. WT-1 TCR (Cell Therapy Catapult) 8.6.6.1. Target Population
8.6.6.2. Sales Forecast
8.6.7. JTCR016 (Juno Therapeutics) 8.6.7.1. Target Population
8.6.7.2. Sales Forecast
8.6.8. MAGE A3/A6 (Kite Pharma) 8.6.8.1. Target Population 8.6.8.2. Sales Forecast
8.6.9. MAGE A3 (Kite Pharma) 8.6.9.1. Target Population 8.6.9.2. Sales Forecast
8.7. Overall TIL Therapy Market 8.7.1. LN-144 (Lion Biotechnologies) 8.7.1.1. Target Population
8.7.1.2. Sales Forecast
8.7.2. TIL Therapy (Nantes University) 8.7.2.1. Target Population
8.7.2.2. Sales Forecast
8.7.3. TIL Therapy (Netherlands Cancer Institute) 8.7.3.1. Target Population
8.7.3.2. Sales Forecast
9. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES 9.1. Chapter Overview
9.2. Introduction
9.3. Haematological Malignancies 9.3.1. Leukaemia and Lymphoma
9.3.1.1. Introduction and Epidemiology: Leukaemia 9.3.1.1.1. Acute Myeloid Leukaemia (AML) 9.3.1.1.2. Chronic Myeloid Leukaemia (CML) 9.3.1.1.3. Acute Lymphocytic Leukaemia (ALL) 9.3.1.1.4. Chronic Lymphocytic Leukaemia (CLL) 9.3.1.2. Introduction and Epidemiology: Lymphoma 9.3.1.3. Current Treatment Landscape
9.3.1.3.1. Targeted Therapies
9.3.1.4. T-Cell Immunotherapy and Research Landscape 9.3.1.4.1. CAR-Ts and Leukaemia/Lymphoma
9.3.1.4.2. TCRs and Leukaemia/Lymphoma
9.3.2. Multiple Myeloma
9.3.2.1. Introduction and Epidemiology 9.3.2.2. Current Treatment Landscape
9.3.2.3. T-Cell Immunotherapy and Research Landscape
9.4. Solid Tumours 9.4.1. Metastatic Melanoma
9.4.1.1. Introduction and Epidemiology 9.4.1.2. Current Treatment Landscape
9.4.1.3. T-Cell Immunotherapy and Research Landscape 9.4.1.3.1. TILs and Metastatic Melanoma
9.4.1.3.2. TIL Research at MD Cancer Research Centre, USA 9.4.1.3.3. TIL Research at Sheba Medical Centre, Israel 9.4.1.3.4. TCRs and Metastatic Melanoma
9.4.1.3.5 CAR-Ts and Metastatic Melanoma
9.4.2. Bladder Cancer
9.4.2.1. Introduction and Epidemiology 9.4.2.2. Current Treatment Landscape
9.4.2.3. T-Cell Immunotherapy and Research Landscape
9.4.3. Kidney Cancer
9.4.3.1. Introduction and Epidemiology 9.4.3.2. Current Treatment Landscape
9.4.3.3. T-Cell Immunotherapy and Research Landscape
9.4.4. Ovarian Cancer
9.4.4.1. Introduction and Epidemiology 9.4.4.2. Current Treatment Landscape
9.4.4.3. T-Cell Immunotherapy and Research Landscape 9.4.4.3.1. CAR-Ts and Ovarian Cancer
9.4.4.3.2. TCRs and Ovarian Cancer
9.4.5. Breast Cancer
9.4.5.1. Introduction and Epidemiology 9.4.5.2. Current Treatment Landscape
9.4.5.3. T-Cell Immunotherapy and Research Landscape 9.4.5.3.1. CAR-Ts and Breast Cancer
9.4.5.3.2. TCRs and Breast Cancer 9.4.5.3.3. TILs and Breast Cancer
9.4.6. Glioblastoma
9.4.6.1. Introduction and Epidemiology 9.4.6.2. Current Treatment Landscape
9.4.6.3. T-Cell Immunotherapy and Research Landscape
10 EMERGING TECHNOLOGIES 10.1. Chapter Overview
10.2. Introduction
10.3. Genome Editing Driving the T-Cell Therapies 10.4. Applications of Genome Editing
10.4.1. Genome Editing Technologies 10.4.1.1. CRISPR/Cas9 System 10.4.1.1.1. Structural Features 10.4.1.1.2. Modularity of the System 10.4.1.1.3. Mechanism of Action
10.4.1.1.4. Targeting Efficiency and Challenges 10.4.1.1.5. Next-GEN CRISPR Technology 10.4.1.1.6. Technology Providers 10.4.1.1.6.1. Editas Medicine 10.4.1.1.6.2 Intellia Therapeutics 10.4.1.1.6.3. CRISPR Therapeutics 10.4.1.2. TALENs 10.4.1.2.1. Structural Features 10.4.1.2.2. Mechanism of Action 10.4.1.2.3. Advantages and Challenges 10.4.1.2.4. Technology Providers 10.4.1.2.4.1. Cellectis
10.4.1.2.4.2. Editas Medicine
10.4.1.3. Endonuclease and megaTAL 10.4.1.3.1. Technology Providers 10.4.1.3.1.1 bluebird bio
10.4.1.4. Zinc Finger Nuclease 10.4.1.4.1. Benefits
10.4.1.4.2. Technology Providers 10.4.1.4.2.1. Sangamo Biosciences
10.5. Designing T-Cell Therapies with ImprovedCharacteristics 10.5.1. Technology for Targeting Multiple Cancers
10.5.1.1. Antibody Coupled T-Cell Receptor, UnumTherapeutics 10.5.1.2. NK Cell Receptor, Celyad
10.5.1.2.1. Long Term Tumour free Survival 10.5.1.2.2. Durable Anti-Tumour Immunity
10.5.2. Technology for Improved Safety 10.5.2.1. Armoured CAR, Juno Therapeutics 10.5.2.2. RheoSwitch Therapeutic System, Intrexon
10.5.2.3. Inducible Caspase9 Safety Switch, BellicumPharmaceuticals 10.5.2.3.1. CaspaCIDe Safety Switch Technology
10.5.2.3.2. CIDeCAR Switch Technology 10.5.2.3.3. GoCAR-T Switch Technology 10.5.2.4. On-Off Switch, Multiple Companies 10.5.2.4.1. Inhibitory CAR (iCAR), Juno Therapeutics 10.5.2.4.2. On-Off Switch, Theravectys
10.5.3. Allogeneic Technology
10.5.3.1. CIK CAR-T Cells, Formula Pharmaceuticals 10.5.3.2. Allogeneic Platform, Celyad
10.5.3.3. Allogeneic Platform, Cellectis
11 VENTURE CAPITAL SUPPORT 11.1. Chapter Overview
11.2. Investors and Innovative Therapies: Trending Together 11.3. Instances of Investments / Grants in T-Cell Therapies 11.4. Growing Venture Capitalist Interest
11.5. Funding Instances: Distribution by Type ofFunding 11.6. Funding Amount: Distribution by Type of Funding
12 COMPANY PROFILES 12.1. Chapter Overview 12.2. Adaptimmune 12.2.1. Company Overview 12.2.2. Financial Information 12.2.3. Product Portfolio 12.2.4. Manufacturing Capabilities 12.2.5. Collaborations
12.2.5.1. Progenitor Cell Therapy 12.2.5.2. Thermofisher / Life Technologies 12.2.5.3. GlaxoSmithKline
12.2.6. Future Outlook
12.3. Altor Bioscience Corporation 12.3.1. Company Overview 12.3.2. Financial Information 12.3.3. Product Portfolio 12.3.4. Patents Portfolio 12.3.5. Collaborations
12.3.5.1. Massachusetts General Hospital and Howard Hughes Medical Institute 12.3.6. Future Outlook 12.4. bluebird bio 12.4.1. Company Overview 12.4.2. Financial Information 12.4.3. Product Portfolio 12.4.4. Collaborations 12.4.4.1. Celgene Corporation 12.4.4.2. Pregenen
12.4.4.3. Five Prime Therapeutics 12.4.4.4. Kite Pharma 12.4.5. Future Outlook 12.5. Cellectis 12.5.1. Company Overview 12.5.2. Financial Information 12.5.3. Product Portfolio 12.5.4. Collaborations 12.5.4.1. CELLforCURE 12.5.4.2. OncoDesign Biotechnology 12.5.4.3. Ohio University
12.5.4.4. Weill Cornell Medical College
Ordering
Order Online -
http://www.biomarketgroup.com/market-research-report/t-cell-immunotherapy-market-2015-2030.html
Order by Fax - using the form below
Order by Post - print the order form below and send to:
BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card: American Express Master Card Visa
Cardholder Name: Expiry Date (MM/YY): Card Number:
CVV Number:
Pay by check:
Please post the check, accompanied by this form, to: BioMarket Group
Björnnäsvägen 21 11419 STOCKHOLM SWEDEN
Pay by wire transfer: Please transfer funds to: Account number: 43521169
Swift code: HANDSESS
IBAN number: SE74 6000 0000 0000 4352 1169 Bank Address: Handelsbanken, Stockholm, Sweden If you have a Marketing Code please enter it below: Marketing Code:
Please supply purchase order number if needed:
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Name:
Email Address:* Job Title: Organization:
EU companies must supply: VAT / BTW / MOMS MWST / IVA / FPA number:
Address: Zip Code: City: State: Country: Phone Number: Fax Number:
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit
http://www.biomarketgroup.com/market-research-report/contacts/
Order Information
Please verify that the product information is correct:
Product Name: T-Cell Immunotherapy Market, 2015-2030
Web Address: http://www.biomarketgroup.com/market-research-report/t-cell-immunotherapy-market-2015-2030.html
Format: PDF
Price: 2199 USD (Single User License)
Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 USD. Delivery within Sweden is subject to VAT at 25%.
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)
http://www.biomarketgroup.com/market-research-report/biomarket-group-full-terms-and-conditions/
